Table 1

Diagnosis of the patients in the respective sets of study: AL according to the WHO 2016 classification and viral or other infections.

DiagnosisAL subtype and complementary testsPTrainingTesting
AML with recurrent genetic abnormalitiesAPL with PML-RARA
(HLA-DR−, CD34−, CD13+, CD33+)
AML with t(6;9) (p23;q34.1); DEK-NUP214
(CD45 weak, CD34+, HLA-DR weak, CD117 weak, CD13+, CD33+)
AML with inv(3) (q21.3q26.2)
(CD45 weak, CD34+, HLA-DR+, CD117+, CD13 weak, MPO weak)
AML with t(9;11) (p21.3;q23.3); MLLT3-KMT2A 314465
AML with mutated NPM1
(HLA-DR+, CD117+, CD13+, CD33+, CD123+)
AML with myelodysplasia-related changesCD45 weak, CD34+, HLA-DR+, CD117+, CD13+, CD33+, CD123+9376140
AML, NOSAcute monoblastic/monocytic leukaemia
(HLA-DR+, CD13+, CD33+, CD64+, CD4+, CD36+, CD11b+)
ALL-B/lymphoma with recurrent genetic abnormalitiesALL-B/lymphoma with t(9;22) (q34.1;q11.2); BCR-ABL1
(CD123+, CD19+, CD22+, CD79a+)
ALL-B/lymphoma, NOSCD19+, CD22+, CD79a+, CD10+, CD20+, CD34+8402143
CD45 weak, CD19+, CD79a+, TdT+, CD10−, CD20−8400146
Viral or other infections53944264
  • The table also indicates the diagnosis and AL subtype with results of the most relevant complementary tests.

  • AL, acute leukaemia; ALL-B, acute lymphoid leukaemia;AML, acute myeloid leukaemia; APL, acute promyelocytic leukaemia;HLA-DR, Human leucocyte antigen; I, number of images; MPO, Myeloperoxidase; NOS, not otherwise specified; P, number of patients.